<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688022</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-E03</org_study_id>
    <secondary_id>2018-002718-11</secondary_id>
    <nct_id>NCT03688022</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor</brief_title>
  <acronym>MT-7117 BA DDI</acronym>
  <official_title>An Open Label, Multicentre, Randomised, 2-cohort, Sequential and Crossover Study to Assess the Relative Oral Bioavailability of MT-7117 Higher Content Tablets Versus MT-7117 Lower Content Tablets and the Pharmacokinetics of MT-7117 Under Various Gastric Conditions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess&#xD;
      the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower&#xD;
      content tablets and the pharmacokinetics of MT-7117 under various gastric conditions (fed and&#xD;
      fasted, and following administration of a proton pump inhibitor and an acidic beverage) in&#xD;
      healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Actual">December 22, 2018</completion_date>
  <primary_completion_date type="Actual">December 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose and up to 48 hours following each single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Pre-dose and up to 48 hours following each single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time zero to infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose and up to 48 hours following each single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious AEs</measure>
    <time_frame>up to 48 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>MT-7117 BA and DDI (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-7117 food effect and DDI (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <description>MT-7117</description>
    <arm_group_label>MT-7117 BA and DDI (fasted)</arm_group_label>
    <arm_group_label>MT-7117 food effect and DDI (fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI</intervention_name>
    <description>Proton pump inhibitor</description>
    <arm_group_label>MT-7117 BA and DDI (fasted)</arm_group_label>
    <arm_group_label>MT-7117 food effect and DDI (fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acidic beverage</intervention_name>
    <description>Acidic beverage</description>
    <arm_group_label>MT-7117 BA and DDI (fasted)</arm_group_label>
    <arm_group_label>MT-7117 food effect and DDI (fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Additional screening criteria check may apply for qualification:&#xD;
&#xD;
          -  Able to provide written informed consent to participate in this study.&#xD;
&#xD;
          -  Healthy and free from clinically significant illness or disease.&#xD;
&#xD;
          -  Caucasian male and female subjects aged 18 to 55 years (inclusive) that are willing&#xD;
             and able to practice acceptable birth control for the duration of the study, as&#xD;
             defined in the Protocol.&#xD;
&#xD;
          -  A body weight of â‰¥50.0 kg and a body mass index (BMI) (Quetelet index) ranging from&#xD;
             18.0 to 30.0 kg/m2 (inclusive) at Screening.&#xD;
&#xD;
          -  Subject is able to understand the nature of the study and any risks involved in&#xD;
             participation, and willing to cooperate and comply with the protocol restrictions and&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Additional screening criteria check may apply for qualification:&#xD;
&#xD;
          -  Previously having received MT-7117.&#xD;
&#xD;
          -  Participation in more than 3 clinical studies* involving administration of an&#xD;
             Investigational Medicinal Product (IMP) in the previous year, or any study* involving&#xD;
             administration of an IMP within 12 weeks (or, if relevant, 5 half-lives, whichever is&#xD;
             the longer) prior to the first dose. (*Disregarding any study Follow-up Periods).&#xD;
&#xD;
          -  Subjects who have received any prescribed systemic or topical medication within 14&#xD;
             days (or, if relevant, 5 half-lives; whichever is longer) prior to the first dose of&#xD;
             IMP.&#xD;
&#xD;
          -  Subjects who have used any non-prescribed systemic or topical medication (including&#xD;
             herbal remedies) within 7 days (or, if relevant, 5 half-lives; whichever is longer)&#xD;
             prior to the first dose of IMP.&#xD;
&#xD;
          -  Clinically relevant abnormal medical history.&#xD;
&#xD;
          -  Family history of long or short QT syndrome, hypokalaemia, syncope or Torsades de&#xD;
             Pointes.&#xD;
&#xD;
          -  Clinically significant 12-lead electrocardiogram (ECG) abnormalities.&#xD;
&#xD;
          -  Blood pressure (supine) at Screening outside the range 90 to 140 mmHg (systolic) or 50&#xD;
             to 90 mmHg (diastolic).&#xD;
&#xD;
          -  Presence or history of severe adverse reaction or allergy to any drug.&#xD;
&#xD;
          -  Presence or history of drug abuse.&#xD;
&#xD;
          -  Presence or history of alcohol abuse.&#xD;
&#xD;
          -  Subjects who use tobacco or nicotine-containing products within 3 months.&#xD;
&#xD;
          -  Test positive for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C&#xD;
             antibody, or human immunodeficiency virus (HIV) 1 &amp; HIV 2 antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Europe Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Centre(s)</name>
      <address>
        <city>Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative Bioavailability and DDI study with MT-7117 and a proton pump inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

